Laura Libby
Internal Medicine · New York, NYNPI 1568607703
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 507 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 507 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Insmed, Inc.$913
- Sanofi$856
- Regeneron Healthcare Solutions, Inc.$762
- plus $4K from 26 others
What the payments were for
- Food & beverage$11,61399%
- Education$961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 124 | $2,139 |
| AstraZeneca | 101 | $2,029 |
| Boehringer Ingelheim | 51 | $1,493 |
| Insmed, Inc. | 37 | $913 |
| Sanofi | 27 | $856 |
| Regeneron Healthcare Solutions, Inc. | 29 | $762 |
| Baxter Healthcare | 15 | $450 |
| Electromed, Inc. | 18 | $428 |
| Advanced Respiratory, Inc | 11 | $297 |
| Philips North America LLC | 12 | $288 |
| Actelion Pharmaceuticals US, Inc. | 9 | $250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $217 |
| Grifols USA, LLC | 8 | $194 |
| Verona Pharma, Inc. | 5 | $161 |
| Amgen | 7 | $154 |
| Paratek Pharmaceuticals, Inc. | 7 | $149 |
| Pulmonx Corporation | 2 | $141 |
| Vifor Pharma, Inc. | 4 | $106 |
| Mylan Specialty L.p. | 4 | $96 |
| Merck | 5 | $88 |
| Novartis | 3 | $86 |
| Mallinckrodt Hospital Products Inc. | 2 | $67 |
| Lilly USA, LLC | 2 | $58 |
| Johnson & Johnson | 3 | $55 |
| Circassia Inc. | 2 | $39 |
| Shionogi Inc | 2 | $38 |
| Genentech USA, Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $37 |
| Pfizer | 2 | $30 |
| United Therapeutics Corporation | 1 | $24 |
| Bayer | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$11,709 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 13 | $196,090 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 164 | $123,207 |
| NucalaMepolizumab | 22 | $87,687 |
| Fasenra PenBenralizumab | 12 | $72,530 |
| EliquisApixaban | 66 | $70,834 |
| Breo ElliptaFluticasone/Vilanterol | 99 | $59,252 |
| Spiriva HandihalerTiotropium Bromide | 51 | $33,881 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 53 | $23,915 |
| OzempicSemaglutide | 18 | $17,176 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $14,784 |
| Spiriva RespimatTiotropium Bromide | 20 | $11,855 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $10,531 |
| LinzessLinaclotide | 13 | $7,267 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $6,053 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $5,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,139 | $300,114350 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $1,493 | $207,94533 claims |
| PfizerEliquis | $30 | $70,83466 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,029 | $30,08275 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.